In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharma: Serious About Change?

Executive Summary

Pharmaceutical companies are attempting to solve unprecedented R&D and commercial challenges via business development, emphasizing cheaper, earlier-stage alliances and building up a base in emerging markets. An analysis of dealmaking trends from 2007 to 2010 shows big companies are embracing new kinds of partners, and shifting away from historic areas of interest to pursue hyper-specialty products and generics.

Related Content

Sanofi/Genzyme: Emblematic of What Big Pharma's Buying Now
Back To School: Big Pharmas Test New Models For Tapping Academia
A Look Back At 2010: In Search Of New Biopharma Models
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2010
Reata's $450 Million Up-Front Haul Sets A Record But Remains An Outlier
Highlights From Pharmaceutical Strategic Alliances: The Importance Of Emerging Markets
Reimbursement: The New Biopharma Investment Hurdle
Orphaned No Longer: Big Pharma Embraces Drugs for Niche Markets
Sanofi Makes its Biggest External Play Yet With Long-Term Regeneron Deal
New Frontiers in Pharma R&D Investment


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts